Delving into the Latest Updates on Aquapharm Biodiscovery Ltd. with Synapse

Overview

A putative haloalkane dehalogenase has been identified in a marine Rhodobacteraceae and subsequently cloned and over‐expressed in Escherichia coli. The enzyme has highest activity towards the substrates 1,6‐dichlorohexane, 1‐bromooctane, 1,3‐dibromopropane and 1‐bromohexane. The crystal structures of the enzyme in the native and product bound forms reveal a large hydrophobic active site cavity. A deeper substrate binding pocket defines the enzyme preference towards substrates with longer carbon chains. Arg136 at the bottom of the substrate pocket is positioned to bind the distal halogen group of extended di‐halogenated substrates.

01 Feb 2012·The Biochemist

The ocean pharmacy: A treasure chest of new drug leads

Author: Best, Simon G. ; Spragg, Andrew Mearns

Over the last 20 years, the pharmaceutical industry has seen a decrease in discovery and success based on computational and combinatorial chemistry, and an increase in base costs imposed by increasing regulatory requirements and a higher rate of failures during the development process1. Couple this to the potential of structural, hence intellectual property overlap between libraries of synthetic compounds and the need for low-cost, scalable and chemically unique new scaffolds, the pharmaceutical industry is starting to re-evaluate the potential of natural products to provide the industry with new drug leads.

Chimica Oggi

Finding NEMO (inhibitors) the search for marine pharmacophores targeting the nuclear factor-κB

Author: Folmer, Florence ; Diederich, Marc ; Jaspars, Marcel ; Schumacher, Marc

A review.Since the early 1960's, marine organisms have provided natural products chemists with a rich source of novel and very diverse metabolites with unprecedented chem. structures.Over the last few decades, significant effort has been placed on the pharmacol. evaluation of marine secondary metabolites.This scientific endeavour, which is often referred to as the search for "Drugs from the Sea", has lead to the discovery of numerous anti-cancer, anti-inflammatory, and antimicrobial compounds, several of which are currently in clin. trials.In the present review, we discuss the potential of marine natural products as pharmacophores for the inhibition of the nuclear factor-κB which has recently been recognized as an important mol. target in both anti-cancer and anti-inflammatory drug discovery.In particular, we focus on marine natural products with lactone moieties, which cover a third of all the currently known NF-κB inhibitors of marine origin.Abbreviations: COX-2, cyclooxygenase-2; IκB, inhibitor of NF-κB; JNK, Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; N.A., not available; NEMO, NF-κB essential modulator; IKK, kinase of IκB; iNOS, inducible nitric oxide synthase; IL, interleukin; NF-κB, nuclear factor-κB; PKC, protein kinase C; PLA₂, phospholipase A₂; TNF-α, tumor necrosis factor-α.

100 Deals associated with Aquapharm Biodiscovery Ltd.

Login to view more data

100 Translational Medicine associated with Aquapharm Biodiscovery Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

5

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

AQP-182	Bacterial Infections More	Pending
AQP-1180 ( NFKB1 x Nrf2 )	Inflammation More	Pending
AQP-1086	Gram-Positive Bacterial Infections More	Pending
AQP-1386 ( Nrf2 )	Inflammation More	Pending
P-216CM	Bacterial Infections More	Pending